|
18.02.2016 06:55:46
|
Strong sales - product launch affected profitability
Navamedic ASA today announced the Company's fourth quarter and full year 2015 financial results. The Company's sales reach all time high levels both in the quarter and for the year, while profitability was affected by the introduction of Navamedic's new product Sippi.
Navamedic posted sales of NOK 65.4 million in the fourth quarter, compared to NOK 61.9 million in the last quarter of 2014. EBITDA for the quarter ended at NOK -0.1 million, compared to NOK 5.3 million the previous year. The Company's net result for the quarter came in at NOK -10.9 million, against NOK -2.2 million if the fourth quarter of 2014.
The reduction in Navamedic's profitability is mainly caused by the international launch of the Company's new urine monitoring system for intensive care patients, Sippi. The new product was launched in the third quarter, and was during the fourth quarter introduced in additional markets. Sippi is currently in test use by hospitals across nine European countries, and is expected to start generating revenues in 2016.
For the full year 2015, Navamedic had sales of NOK 248.3 million, which an 11 per cent increase from 2014. Affected by the acquisition of Observe Medical and the launch of its product Sippi, Navamedic's EBITDA ended at NOK 8.8 million, compared to the 2014 EBITDA of NOK 15.7 million. Net result for 2015 was NOK -10.9 million, against NOK -0.7 the previous year.
Going forward, Navamedic expects continued sales growth for its Nordic pharma and healthcare business. The Company's main priority in this business remains margin improvements. The new product Sippi is a potential game changer in the monitoring fluid balance in seriously ill patients. In parallel with the introduction of Sippi in additional markets, extensive product development is ongoing. During 2016, Sippi will be able to upload patient data automatically into the hospital's data system
For further information, please contact CEO Tom Rönnlund, telephone +46 727 320 321
Navamedic ASA is a Norwegian medtech and pharmaceutical products company,delivering products to patients, hospitals and pharmacies in the Nordic and Benelux markets. The Group's Medtech business has developed and is currently introducing the next generation digital urine meter Sippi ®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange(ticker: NAVA).
www.navamedic.com
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via Globenewswire
HUG#1987105
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Navamedic ASAShsmehr Nachrichten
|
11.02.25 |
Ausblick: Navamedic AS präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
|
28.01.25 |
Erste Schätzungen: Navamedic AS stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) | |
|
30.10.24 |
Ausblick: Navamedic AS vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
16.10.24 |
Erste Schätzungen: Navamedic AS informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu Navamedic ASAShsmehr Analysen
Aktien in diesem Artikel
| Navamedic ASAShs | 1,80 | -0,55% |
|
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.